Baird lowered the firm’s price target on Thermo Fisher to $524 from $589 and keeps an Outperform rating on the shares. The firm said they reported mixed 3Q results and lowered 2023 core organic revenue and EPS growth assumptions, with management highlighting no improvement in bioproduction orders, increased customer spend caution, and a deteriorating China macro environment throughout 3Q.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TMO:
- Thermo Fisher downgraded to Sector Weight from Overweight at KeyBanc
- Thermo Fisher Scientific Earnings Report: Did it Beat Expectations?
- Wells ups Thermo Fisher to Equal Weight with ‘bear thesis boxes finally checked’
- Thermo Fisher upgraded to Equal Weight from Underweight at Wells Fargo
- Thermo Fisher sees FY23 adjusted EPS $21.75, consensus $26